{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-110696","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2025-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.283757+00:00","generated_at":"2026-05-22T22:52:17.452528+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ARS Pharma and ALK co-promote neffy nasal spray to up to 9,000 U.S. pediatricians","bullets":["Co-promotion agreement with ALK-Abelló, Inc. for neffy (epinephrine nasal spray) targeting pediatricians and other prescribers.","ALK starts promotion activities May 2025, must meet ramp-up milestones and minimum detail requirements; non-compete on injectable epinephrine.","ARS books all U.S. sales; ALK receives base fee (first-year deferred) and performance bonuses from year 2: 30% of net sales above preset market share thresholds.","Agreement expires after 4 years; termination provisions include for convenience (with fee) and change of control (mid-seven to low eight-digit fee)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-110696","json":"https://secwatch.observer/filing/0001193125-25-110696.json","markdown":"https://secwatch.observer/filing/0001193125-25-110696.md","text":"https://secwatch.observer/filing/0001193125-25-110696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312525110696/0001193125-25-110696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312525110696/d26679d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T22:52:17.452528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}